In deal with North Carolina biotech, Vertex takes on Huntington’s disease

In deal with North Carolina biotech, Vertex takes on Huntington’s disease

Publication date: Oct 01, 2019

Vertex Pharmaceuticals, the Boston drug maker best known for its cystic fibrosis treatments, continues to branch out, cutting a deal with a North Carolina-based biotech firm that is targeting several serious illnesses, including the fatal genetic disorder Huntington’s disease.

The first collaboration that Ribometrix will focus on is Huntington’s disease.

-Targeting RNA is a potentially powerful new approach” for treating diseases, said Mark Bunnage, a senior vice president and site head for Boston research at Vertex.

Vertex is largely known for its groundbreaking but costly treatments for cystic fibrosis, another rare disease.

Concepts Keywords
Biotech Industries
Bob Dylan Cystic fibrosis
Boston Huntingtons
Brain Life sciences
CEO Medical specialties
Cystic Fibrosis Vertex Pharmaceuticals
Durham Drug maker
Folk Singer
Genetic Disorder
Globe
Huntington
Molecule
Muscular Dystrophy
Nerve
North Carolina
Pain
Prime
Progressive
Rare Disease
Ribonucleic Acid
RNA
Sickle
Solomon
Woody Guthrie

Semantics

Type Source Name
drug DRUGBANK Coenzyme M
disease MESH sickle cell disease
disease DOID muscular dystrophy
disease MESH muscular dystrophy
disease MESH rare disease
gene UNIPROT MARK1
gene UNIPROT GPR15
disease MESH cystic fibrosis
disease DOID cystic fibrosis
disease MESH genetic disorder

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *